.png){kind=icon}
.png){kind=icon}
Return
Sickle cell disease
.png){kind=icon}
OA
AI
DOI：10.1038/nrdp.2018.10.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB, which encodes haemoglobin subunit beta. The incidence is estimated to be between 300,000 and 400,000 neonates globally each year, the majority in sub-Saharan Africa. Haemoglobin molecules that include mutant sickle beta-globin subunits can polymerize; erythrocytes that contain mostly haemoglobin polymers assume a sickled form and are prone to haemolysis. Other pathophysiological mechanisms that contribute to the SCD phenotype are vaso-occlusion and activation of the immune system. SCD is characterized by a remarkable phenotypic complexity. Common acute complications are acute pain events, acute chest syndrome and stroke; chronic complications (including chronic kidney disease) can damage all organs. Hydroxycarbamide, blood transfusions and haematopoietic stem cell transplantation can reduce the severity of the disease. Early diagnosis is crucial to improve survival, and universal newborn screening programmes have been implemented in some countries but are challenging in low-income, high-burden settings.
Keywords:
QUALITY-OF-LIFE
ACUTE CHEST SYNDROME
NEWBORN SCREENING-PROGRAM
SILENT CEREBRAL INFARCTS
DOPPLER FLOW VELOCITIES
PULMONARY-HYPERTENSION
HYDROXYUREA THERAPY
FETAL-HEMOGLOBIN
CONTROLLED-TRIAL
UNITED-STATES
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
N
IF:
60.6
Papers:
645
Citations:
3.8W
Organization
View more organizations